검색
Bicycle Therapeutics PLC
BCYC관심 목록에 추가
3.735USD
+0.105+2.89%
시장 운영 시간 09/22, 12:20（ET）
188.16M시가총액
손실P/E TTM
{index_name} 정보 Bicycle Therapeutics PLC 회사
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics PLC 프로필
종목 코드 BCYC
회사 이름Bicycle Therapeutics PLC
상장일May 23, 2019
CEOLee (Kevin)
직원 수305
유형Depository Receipt
회계 연도 종료May 23
주소Blocks A & B, Portway Building
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United Kingdom
우편 번호CB21 6GS
전화11441223261503
웹사이트https://www.bicycletherapeutics.com/
종목 코드 BCYC
상장일May 23, 2019
CEOLee (Kevin)
Bicycle Therapeutics PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
758.00
-300.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
317.14K
+13.10%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
69.97K
-4.22%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Corporate Development Officer
Chief Corporate Development Officer
39.58K
+35.99%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
25.38K
+27.83%
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
6.01K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
758.00
--
자주 묻는 질문
Bicycle Therapeutics PLC의 상위 5대 주주는 누구인가요?
Bicycle Therapeutics PLC의 상위 5대 주주는 다음과 같습니다: Dr. Kevin Lee, Ph.D.
Bicycle Therapeutics PLC(BCYC)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Bicycle Therapeutics PLC의 주식을 보유한 기관은 총 250곳이며, 이들이 보유한 주식의 총 가치는 약 33.87M로 전체 발행 주식의 67.23%를 차지합니다. 이는 2025Q4 대비 -23140757.00 증가한 수치입니다.